Scolaris Content Display Scolaris Content Display

Administration orale de bêtamimétiques pour réduire les accouchements prématurés chez les femmes ayant une grossesse gémellaire

Appendices

Appendix 1. Search strategy

Authors wrote and ran:

MEDLINE (OvidSP) (January 1966 to 31 July 2015)

1. randomized controlled trial.pt.

2. controlled clinical trial.pt.

3. randomized.ab.

4. placebo.ab.

5. drug therapy.fs.

6. randomly.ab.

7. trial.ab.

8. groups.ab.

9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8

10. exp Pregnancy, Twin/

11. (twin adj6 pregnanc$).mp.

12. (twin$).mp.

13. 10 or 11 or 12

14. exp Adrenergic beta‐Agonists/

15. (adrenergic adj6 beta$).mp.

16. betamimetics.mp.

17. 14 or 15 or 16

18. 9 and 13 and 17

EMBASE (OvidSP) (EMBASE (January 1985 to 31 July 2015)

1. randomized controlled trial/

2. controlled clinical trial/

3. random*.tw.

4. placebo*.tw.

5. assign*.tw.

6. allocat*.tw.

7. (doubl* near/6 blind*).tw.

8. (singl* near/6 blind*).tw.

9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8

10. exp Pregnancy, Twin/

11. (twin near/6 pregnanc*).tw.

12. (twin*).tw.

13. 10 or 11 or 12

14. exp Adrenergic beta‐Agonists/

15. (adrenergic near/6 beta*).tw.

16. betamimetics.tw.

17. 14 or 15 or 16

18. 9 and 13 and 17

'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 1

'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.

'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 2

'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Comparison 1 Oral betamimetic versus placebo, Outcome 1 Preterm labour.
Figuras y tablas -
Analysis 1.1

Comparison 1 Oral betamimetic versus placebo, Outcome 1 Preterm labour.

Comparison 1 Oral betamimetic versus placebo, Outcome 2 Prelabour rupture of membranes.
Figuras y tablas -
Analysis 1.2

Comparison 1 Oral betamimetic versus placebo, Outcome 2 Prelabour rupture of membranes.

Comparison 1 Oral betamimetic versus placebo, Outcome 3 Preterm birth (less than 37 weeks' gestation).
Figuras y tablas -
Analysis 1.3

Comparison 1 Oral betamimetic versus placebo, Outcome 3 Preterm birth (less than 37 weeks' gestation).

Comparison 1 Oral betamimetic versus placebo, Outcome 4 Preterm birth (less than 34 weeks' gestation).
Figuras y tablas -
Analysis 1.4

Comparison 1 Oral betamimetic versus placebo, Outcome 4 Preterm birth (less than 34 weeks' gestation).

Comparison 1 Oral betamimetic versus placebo, Outcome 5 Neonatal mortality.
Figuras y tablas -
Analysis 1.5

Comparison 1 Oral betamimetic versus placebo, Outcome 5 Neonatal mortality.

Comparison 1 Oral betamimetic versus placebo, Outcome 6 Low birthweight (less than 2500 g).
Figuras y tablas -
Analysis 1.6

Comparison 1 Oral betamimetic versus placebo, Outcome 6 Low birthweight (less than 2500 g).

Comparison 1 Oral betamimetic versus placebo, Outcome 7 Small‐for‐gestational age (birthweight less than 10th centile).
Figuras y tablas -
Analysis 1.7

Comparison 1 Oral betamimetic versus placebo, Outcome 7 Small‐for‐gestational age (birthweight less than 10th centile).

Comparison 1 Oral betamimetic versus placebo, Outcome 8 Birthweight (not prespecified).
Figuras y tablas -
Analysis 1.8

Comparison 1 Oral betamimetic versus placebo, Outcome 8 Birthweight (not prespecified).

Comparison 1 Oral betamimetic versus placebo, Outcome 9 Respiratory distress syndrome.
Figuras y tablas -
Analysis 1.9

Comparison 1 Oral betamimetic versus placebo, Outcome 9 Respiratory distress syndrome.

Comparison 1 Oral betamimetic versus placebo, Outcome 10 Maternal death.
Figuras y tablas -
Analysis 1.10

Comparison 1 Oral betamimetic versus placebo, Outcome 10 Maternal death.

Summary of findings for the main comparison. Oral betamimetic versus placebo for pregnant women with a twin pregnancy to prevent preterm birth

Oral betamimetic versus placebo for pregnant women with a twin pregnancy to prevent preterm birth

Patient or population: pregnant women with a twin pregnancy
Settings: studies were located in England, Ireland, Sount Africa, Sweden and Zimbabwe
Intervention: oral betamimetic

Comparison: placebo

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Control

Oral betamimetic versus placebo

Preterm labour
Follow‐up: 10‐16 weeks

Study population

RR 0.37
(0.17 to 0.78)

194
(2 studies)

⊕⊕⊝⊝
low1,2

179 per 1000

66 per 1000
(30 to 140)

Moderate

314 per 1000

116 per 1000
(53 to 245)

Prelabour rupture of membranes
Follow‐up: 8‐16 months

Study population

RR 1.42
(0.42 to 4.82)

144
(1 study)

⊕⊕⊝⊝
low3

57 per 1000

81 per 1000
(24 to 275)

Preterm birth (less than 37 weeks' gestation)
Follow‐up: 6‐20 weeks

Study population

RR 0.85
(0.65 to 1.10)

276
(4 studies)

⊕⊕⊝⊝
low3

478 per 1000

406 per 1000
(311 to 526)

Moderate

427 per 1000

363 per 1000
(278 to 470)

Very preterm birth (less than 34 weeks' gestation)
Follow‐up: 8‐16 months

Study population

RR 0.47
(0.15 to 1.50)

144
(1 study)

⊕⊕⊝⊝
low3

114 per 1000

54 per 1000
(17 to 171)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Unclear risk of selection bias (‐1).
2 Few events and small sample size (‐1).
3 Wide confidence interval crossing the line of no effect, few events and small sample size (‐2).

Figuras y tablas -
Summary of findings for the main comparison. Oral betamimetic versus placebo for pregnant women with a twin pregnancy to prevent preterm birth
Comparison 1. Oral betamimetic versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Preterm labour Show forest plot

2

194

Risk Ratio (M‐H, Fixed, 95% CI)

0.37 [0.17, 0.78]

2 Prelabour rupture of membranes Show forest plot

1

144

Risk Ratio (M‐H, Fixed, 95% CI)

1.42 [0.42, 4.82]

3 Preterm birth (less than 37 weeks' gestation) Show forest plot

4

276

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.65, 1.10]

4 Preterm birth (less than 34 weeks' gestation) Show forest plot

1

144

Risk Ratio (M‐H, Fixed, 95% CI)

0.47 [0.15, 1.50]

5 Neonatal mortality Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

5.1 Assuming independence between twins

3

452

Risk Ratio (M‐H, Random, 95% CI)

0.90 [0.15, 5.37]

5.2 Assuming complete correlation between twins

3

226

Risk Ratio (M‐H, Random, 95% CI)

0.74 [0.23, 2.38]

6 Low birthweight (less than 2500 g) Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

6.1 Assuming independence between twins

2

366

Risk Ratio (M‐H, Random, 95% CI)

1.19 [0.77, 1.85]

6.2 Assuming complete correlation between twins

2

183

Risk Ratio (M‐H, Random, 95% CI)

1.09 [0.81, 1.47]

7 Small‐for‐gestational age (birthweight less than 10th centile) Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

7.1 Assuming independence between twins

2

178

Risk Ratio (M‐H, Random, 95% CI)

0.90 [0.41, 1.99]

7.2 Assuming complete correlation between twins

2

89

Risk Ratio (M‐H, Random, 95% CI)

0.95 [0.42, 2.13]

8 Birthweight (not prespecified) Show forest plot

3

478

Mean Difference (IV, Fixed, 95% CI)

111.22 [22.21, 200.24]

9 Respiratory distress syndrome Show forest plot

2

Risk Ratio (M‐H, Fixed, 95% CI)

Subtotals only

9.1 Assuming independence between twins

2

388

Risk Ratio (M‐H, Fixed, 95% CI)

0.30 [0.12, 0.77]

9.2 Assuming complete correlation between twins

2

194

Risk Ratio (M‐H, Fixed, 95% CI)

0.35 [0.11, 1.16]

10 Maternal death Show forest plot

1

144

Risk Ratio (M‐H, Fixed, 95% CI)

2.84 [0.12, 68.57]

Figuras y tablas -
Comparison 1. Oral betamimetic versus placebo